74 completed, 20 terminated, 11 recruiting, 9 unknown. 137 Phase 2, 17 Phase 1, 14 Phase 3.
Follow Urticaria: new trials by email Literature Review of Urticaria trials Research Report on Urticaria
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial to Evaluate the Efficacy and Safety of AK139 in Participants With Chronic Spontaneous Urticaria AK139, Placebo - Chronic Spontaneous Urticaria | Phase 2 | Not yet recruiting | Akeso | 201 | 2026-10-21 | 2026-10-15 |
| A Phase 2 Study of MG-K10 in Chronic Spontaneous Urticaria MG-K10 Injection, Matching Placebo - Chronic Urticaria, Idiopathic | Phase 2 | Not yet recruiting | Shanghai Mabgeek Biotech.Co.Ltd | 60 | 2026-09-23 | 2026-09-24 |
| Apremilast Added to Antihistamines in Chronic Urticaria Apremilast, Second-generation H1 antihistamine - Chronic Urticaria, Chronic Spontaneous Urticaria | Phase 2 | Enrolling by invitation | Rashid Latif Medical College | 86 | 2026-09-23 | 2026-09-30 |
| A Study to Assess the Efficacy and Safety of THB335 in Adults With Chronic Spontaneous Urticaria (CSU) THB335 Lower Dose, THB335 Higher Dose, Placebo - Chronic Spontaneous Urticaria (CSU), Chronic Idiopathic Urticaria | Phase 2 | Recruiting | Calixis Inc. | 81 | 2026-09-15 | 2026-11-02 |
| A Study of Efficacy and Safety of TLL-018 in CSU Participants With Inadequate Response to 2nd-generation H1-AHs TLL-018 tablets, Placebo - Chronic Spontaneous Urticaria (CSU) | Phase 2 | Not yet recruiting | Hangzhou Highlightll Pharmaceutical Co., Ltd | 140 | 2026-09-10 | 2026-08-24 |
| A Phase Ib/IIa Study Assessing the Rapid Onset Characteristics of TLL-018 for Moderate-to-Severe CSU With Inadequate Response to Second-Generation H1 Antihistamines TLL-018, Placebo - Chronic Spontaneous Urticaria (CSU) | Phase 1 / Phase 2 | Not yet recruiting | Hangzhou Highlightll Pharmaceutical Co., Ltd | 36 | 2026-08-15 | 2026-08-24 |
| A Clinical Trial of HRS-3095 in Patients With Chronic Spontaneous Urticaria HRS-3095 Tablet, HRS-3095 Tablet Placebo - Chronic Spontaneous Urticaria | Phase 2 | Not yet recruiting | Chengdu Suncadia Medicine Co., Ltd. | 190 | 2026-07-01 | 2026-05-29 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT001 Following Intravenous Administration in Participants With Chronic Spontaneous Urticaria (CSU) BBT001, Placebo - Chronic Spontaneous Urticaria | Phase 1 / Phase 2 | Recruiting | Bambusa Therapeutics | 48 | 2026-06-29 | 2026-07-22 |
| Phase 2 Study of Lesigercept in Adult Patients With Chronic Spontaneous Urticaria Who Are Inadequately Controlled by H1-Antihistamines Lesigercept, Placebo - Allergic Diseases, Chronic Spontaneous Urticaria (CSU) | Phase 2 | Recruiting | Yuhan Corporation | 150 | 2026-03-26 | 2026-04-15 |
| Study of the Efficacy and Safety of ICP-332 in Participants With Chronic Spontaneous Urticaria ICP-332 Tablets, ICP-332 placebo Tablets - Chronic Spontaneous Urticaria (CSU) | Phase 2 / Phase 3 | Recruiting | Beijing InnoCare Pharma Tech Co., Ltd. | 344 | 2026-02-13 | 2026-04-21 |
| Ritlecitinib (PF-06651600) in Participants With Chronic Spontaneous Urticaria Ritlecitinib - Chronic Spontaneous Urticaria, CSU | Phase 2 | Withdrawn | Ahuva D Cices | 2025-12-31 | 2025-12-09 | |
| Study of CM512 Injection in Subjects With Chronic Spontaneous Urticaria(CSU) CM512 injection, placebo - Chronic Spontaneous Urticaria (CSU) | Phase 2 | Recruiting | Keymed Biosciences Co.Ltd | 48 | 2025-11-27 | 2026-04-09 |
| A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults. Ritlecitinib 50 mg, Ritlecitinib 100 mg, Placebo - 50 mg - Chronic Spontaneous Urticaria | Phase 2 | Recruiting | Pfizer | 200 | 2025-10-30 | 2026-10-26 |
| Improving Deceased-Donor Kidney Transplant Outcomes Via a Single Intragraft Injection of C1 Esterase Inhibitor (IMPROVE TRIAL) Berinert, Placebo for Berinert - Kidney Transplant | Phase 2 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 180 | 2025-09-22 | 2026-02-27 |
| An Outpatient Study of the Efficacy of ARS-2 in Patients With Chronic Spontaneous Urticaria Placebo, 0.5 mg epinephrine, 1 mg epinephrine - Urticaria Chronic | Phase 2 | Recruiting | ARS Pharmaceuticals, Inc. | 42 | 2025-07-09 | 2026-09-16 |
| Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU) BLU-808, Placebo - Chronic Inducible Urticaria, Chronic Spontaneous Urticaria | Phase 2 | Active not recruiting | Blueprint Medicines Corporation | 105 | 2025-05-28 | 2026-07-22 |
| Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria Remibrutinib, Placebo - Chronic Urticaria (CU): Chronic Inducible Urticaria (CINDU) and Chronic Spontaneous Urticaria (CSU) | Phase 2 | Recruiting | Novartis Pharmaceuticals | 44 | 2025-05-22 | 2026-09-28 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HS-10561 Capsule in Healthy Chinese Adults and Patients With Chronic Spontaneous Urticaria. HS-10561, Placebo - Chronic Spontaneous Urticaria | Phase 1 / Phase 2 | Not yet recruiting | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 150 | 2025-03-31 | 2025-03-07 |
| Phase 2b Study of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria (CSU) EVO756, Placebo control - Chronic Spontaneous Urticaria | Phase 2 | Completed | Evommune, Inc. | 182 | 2025-03-20 | 2026-07-01 |
| Oral Deucrictibant for Prophylactic and Acute Treatment in Hereditary Angioedema Patients Deucrictibant XR tablet, Placebo comparator to XR tablet, Deucrictibant 20 mg capsule - Hereditary Angioedema (HAE), Angioedema | Phase 1 / Phase 2 | Recruiting | Institute for Asthma and Allergy | 10 | 2025-03-10 | 2025-07-02 |
Showing 20 of 137. Sign in to see all of them.
Chronic Urticaria (61) · Angioedemas, Hereditary (35) · Angioedema (14) · Cryopyrin-Associated Periodic Syndromes (11) · Pruritus (11) · Hereditary Angioedema Types I and II (8) · Chronic Inducible Urticaria (6) · Cold Urticaria (6) · Urticaria, Solar (4) · Hypersensitivity (3) · Immune System Diseases (3) · Skin Diseases (3) · Bronchiolitis Obliterans Syndrome (2) · Familial dermographism (2)
Hypersensitivity, Immediate (137) · Skin and Connective Tissue Diseases (137) · Skin Diseases, Vascular (135) · Hypersensitivity (134) · Immune System Diseases (134) · Skin Diseases (134) · Pathological Conditions, Signs and Symptoms (82) · Pathologic Processes (78) · Disease Attributes (77) · Chronic Disease (76) · Cardiovascular Diseases (47) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (47) · Vascular Diseases (47) · Genetic Diseases, Inborn (45)
Omalizumab (13) · Complement C1 Inhibitor Protein (9) · SERPING1 protein, human (5) · conestat alfa (5) · Sodium Chloride (3) · berotralstat (3) · canakinumab (3) · ligelizumab (3) · rilonacept (3) · AK002 (2) · Epinephrine (2) · IONIS-PKK-LRx (2) · PF-06651600 (2) · avoralstat (2) · bilastine (2)
Novartis Pharmaceuticals (9) · Charite University, Berlin, Germany (8) · Genentech, Inc. (6) · Shire (6) · BioCryst Pharmaceuticals (5) · Johns Hopkins University (4) · Pharming Technologies B.V. (4) · CSL Behring (3) · Jasper Therapeutics, Inc. (3) · National Institute of Allergy and Infectious Diseases (NIAID) (3) · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) (3) · Pharvaris Netherlands B.V. (3) · ARS Pharmaceuticals, Inc. (2) · Allakos Inc. (2) · Astria Therapeutics, Inc. (2)
United States (69) · Germany (58) · Poland (25) · Spain (24) · Canada (23) · United Kingdom (20) · France (16) · Hungary (16) · Italy (15) · China (14) · Netherlands (14) · Australia (13) · Bulgaria (13) · Czechia (11) · Japan (11)
Marcus Maurer, MD (4) · Anurag Relan, MD (2) · Karoline Krause, MD (2) · M. M. Levi, Prof. Dr. (2) · Marcus Maurer, Prof. (2) · Ahuva Cices, MD (1) · Baek-Hwan Cho, MD., PhD (1) · Bruno Giannetti, MD (1)
PMID 36326435, PMID 36408587, PMID 34773261, PMID 36440464, PMID 12384926, PMID 15201414, PMID 15334472, PMID 16899778, PMID 17478385, PMID 18645136, PMID 18668591, PMID 19767078, PMID 20674826, PMID 20920772, PMID 21356079, PMID 21762974, PMID 22136279, PMID 22294344, PMID 22583335, PMID 23535096, PMID 23878046, PMID 23987198, PMID 24712435, PMID 25223501, PMID 25601538, PMID 25629740, PMID 26016741, PMID 26171584, PMID 27143789, PMID 27931305, PMID 28118536, PMID 28284978, PMID 28389393, PMID 28754491, PMID 29974963, PMID 30044938, PMID 30993784, PMID 31577874, PMID 32827729, PMID 33397449, PMID 34161665, PMID 34863258, PMID 35219377, PMID 35294812, PMID 35820771, PMID 35869554, PMID 36774155, PMID 36973954, PMID 37492920, PMID 37866460
2023 (4), 2017 (3), 2018 (3), 2019 (3), 2004 (1), 2009 (1), 2014 (1), 2015 (1), 2016 (1), 2025 (1), ZIAAR041138-08 (1)